Advertisement

Behçet’s Syndrome: From Aetiology to Treatment

  • Richard J. Powell
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 528)

Keywords

Genital Ulcer Chimeric Monoclonal Antibody Posterior Uveitis Retinal Vasculitis Mucocutaneous Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frassantio, M.A., Dammacco, R., Cafforio, P., et al., 1999, The polarization of the immune response in Behçet’s disease. Arthritis Rheum. 42: 1967–1974.Google Scholar
  2. 2.
    Zouboulis, Ch.C., Kötter, I., Djawari, D., et al., 2003, Current epidemiological data from the German registry of Adamantiades-Behçet’s disease. In Adamantiades-Behçet’s Disease (Ch.C. Zouboulis, ed.), Kluwer/Plenum, London, pp. 43–48.Google Scholar
  3. 3.
    Kone-Paut, I., Geisler, I., Wechsler, B., et al., 1999, Familial aggregation in Behçet’s disease: High frequency in siblings and parents of paediatric probands. J. Pediatr. 135: 89–93.PubMedGoogle Scholar
  4. 4.
    Gul, A., Inane, M., Ocal, L., et al., 2000, Familial aggregation of Behçet’s disease in Turkey. Ann. Rheum. Dis. 50: 622–625.Google Scholar
  5. 5.
    Cohen, R., Metzger, M., Nahir, T., et al., 2002, Association of the MIC-A gene and HLA-B51 with Behçet’s disease in Arabs and non-Ashkenazi Jews in Israel. Ann. Rheum. Dis. 61: 157–160.CrossRefPubMedGoogle Scholar
  6. 6.
    Wallace, G.R., Verity, D.H., Delamaine, L.J., et al., 1999, MIC-A allele profiles and HLA class I associations in Behçet’s disease. Immunogenetics 49: 613–617.CrossRefPubMedGoogle Scholar
  7. 7.
    Gul, A., Hajeer, A.H., Worthington, J., et al., 2001, Linkage mapping of a novel susceptibility locus for Behçet’s disease to chromosome 6p22–23. Ann. Rheum. Dis. 44: 2693–2696.Google Scholar
  8. 8.
    Hasan, A., Fortune, F., Wilson, A., et al., 1996, Role of γδ T cells in pathogenesis and diagnosis of Behçet’s disease. Lancet 347: 789–794.CrossRefPubMedGoogle Scholar
  9. 9.
    Yurdakul, S., Mat, C., Tuzun, Y., et al., 2001, A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 44: 2686–2692.CrossRefPubMedGoogle Scholar
  10. 10.
    Calguneri, M., Kiraz, S., Ertenli, I., et al., 1996, The effect of prophylactic penicllin treatment on the course of arthritis episodes in patients with Behçet’s disease. Arthritis Rheum. 39: 2062–2065.PubMedGoogle Scholar
  11. 11.
    Yazici, H., Pazarli, H., Barnes, C.G., et al., 1990, A controlled trial of azathioprine in Behçet’s syndrome. N. Engl. J. Med. 322: 281–285.PubMedGoogle Scholar
  12. 12.
    Hamuryudan, V., Ozyazgan, Y., Hizli, N., et al., 1997, Azathioprine in Behçet’s syndrome. Arthritis Rheum. 40: 760–774.Google Scholar
  13. 13.
    Mudun, B.A., Ergen, A., Ipcioglu, S.U., et al., 2001, Short-term chlorambucil for refractory uveitis in Behçet’s disease. Ocul. Immunol. Inflamm. 9: 219–229.PubMedGoogle Scholar
  14. 14.
    Diaz-Llopis, M., Cervera, M., and Menezo, J.L., 1990, Cyclosporin A treatment of Behçet’s disease: A long-term study. Cur. Eye Res. 9: 17–23.Google Scholar
  15. 15.
    Sloper, C.M.L., Powell, R.J., and Dua, H.S., 1999, Tacrolimus (FK 506) in the treatment of posterior uveitis refractory to cyclopsorine. Ophthalmology 106: 723–728.CrossRefPubMedGoogle Scholar
  16. 16.
    Alpsoy, E., Durusoy, C., Yilmaz, E., et al., 2002, Interferon alfa-2a in the treatment of Behçet disease: A randomized placebo-controlled and double-blind study. Arch. Dermatol. 138: 467–471.CrossRefPubMedGoogle Scholar
  17. 17.
    Jorizzo, J.L., White, W.L., Wise, C.M., et al., 1991 Low dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet’s disease. J. Am. Acad. Dermatol. 24: 973–978.PubMedGoogle Scholar
  18. 18.
    Yasui, K., Ohta, K., Kobayashi, M., et al., 1996, Successful treatment of Behçet disease with pentoxifylline. Ann. Intern. Med. 124: 891–893.PubMedGoogle Scholar
  19. 19.
    Hamza, M., Ayed, K., and Ayed, H.B., 1982, Treatment of Behçet’s disease with levamisole. Arthritis Rheum. 25: 714–715.PubMedGoogle Scholar
  20. 20.
    Keifer, J.A., Guttridge, D.C., Ashburner, B.P., et al., 2001, Inhibition of NFκB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. 276: 22382–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Hamuryudan, V., Mat, C., Saip, S., et al., 1998, Thalidomide in the treatment of mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placeob-controlled trial. Ann. Intern. Med. 128: 443–450.PubMedGoogle Scholar
  22. 22.
    Bastuji-Garin, S., Ochonicky, S., Bouche, P., et al, 2002, Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatological patients. J. Invest. Dermatol. 119: 1020–1026.CrossRefPubMedGoogle Scholar
  23. 23.
    Powell, R.J., and Gardner-Medwin, J.M.M., 1994, Guideline for the clinical use and dispensing of thalidomide. Postgrad. Med. J. 70: 901–904.PubMedGoogle Scholar
  24. 24.
    Zeldis, J.B., Williams, B.A., Thomas, S.D., et al., 1999, S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. 21: 319–330.CrossRefPubMedGoogle Scholar
  25. 25.
    Raje, N., and Anderson, K.C., 2002, Thalidomide and immunomodulatory drugs as cancer therapy. Cur. Opin. Oncol. 14: 635–640.Google Scholar
  26. 26.
    Guckian, M., Dransfield, I., Hay, P. et al., 2000, Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin. Exp. Immunol. 121: 472–479.CrossRefPubMedGoogle Scholar
  27. 27.
    Elliott, M.J., Maini, R.N., Feldmann, M., et al., 1994, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110.PubMedGoogle Scholar
  28. 28.
    Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al., 2002, Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 359: 1541–1549.CrossRefPubMedGoogle Scholar
  29. 29.
    Keating, G.M., and Perry, C.M., 2002, Infliximab: An updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 16: 111–148.CrossRefPubMedGoogle Scholar
  30. 30.
    Keane, J., Gershon, S., Wise, R., et al., 2001, Tuberculosis associated with infliximab. A tumour necrosis factor alpha neutralising agent. N. Engl. J. Med. 345: 1098–1104.CrossRefPubMedGoogle Scholar
  31. 31.
    De Rosa, F.G., Bonora, S., and Di Perri, G., 2002, Tuberculosis and treatment with infliximab. N. Engl. J. Med. 346: 623–626.PubMedGoogle Scholar
  32. 32.
    Munoz-Fernandez, S., Hidalgo, V., Fernandez-Melon, J., et al., 2001, Effect of infliximab on threatening panuveitis in Behcet’s disease. Lancet 358: 1644.PubMedGoogle Scholar
  33. 33.
    Hassard, P.V., Binder, S.W., Nelson, V., et al., 2001, Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: A case report. Gastroenterology 120: 995–999.PubMedGoogle Scholar
  34. 34.
    Goossens, P.H., Verburg, R.J., and Breedveld, F.C., 2001, Remission of Behçet’s syndrome with tumor necrosis factor α blocking therapy. Ann. Rheum. Dis. 60: 637–638.CrossRefPubMedGoogle Scholar
  35. 35.
    Buckland, M.S., O’Grady, C., and Helbert, M.R., 2002, Infliximab in the treatment of soft tissue inflammation of Behçet’s disease. CPD Bull. Immunol. Allergy 2: 55–57.Google Scholar
  36. 36.
    Melikoglu, M., Fresko, I., Mat, C., et al., 2002, A double blind placebo controlled trial of etanercept on the mucocutaneous lesions of Behçet’s syndrome. In Programme and Abstracts. 10th International Conference on Behçet’s Disease, Berlin, p. 68.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Richard J. Powell
    • 1
  1. 1.Department of Clinical Immunology, Queens Medical CentreUniversity of NottighamNottinghamUK

Personalised recommendations